(Q36107945)

12 August 2017

CD73: A potential biomarker for anti-PD-1 therapy (English)

1 reference

12 August 2017

0 references

Michael H Kershaw

0 references

Phillip K Darcy

0 references

Sherene Loi

0 references

Clare Y Slaney

1 reference

12 August 2017

Paul A Beavis

1 reference

12 August 2017

John Stagg

1 reference

12 August 2017

Nicole Milenkovski

1 reference

12 August 2017

Melissa A Henderson

1 reference

12 August 2017

5 May 2015

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

1 reference

12 August 2017

e1046675

1 reference

A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

Immunological mechanisms of the antitumor effects of supplemental oxygenation

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

Adenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma model

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

Blockade of A2A receptors potently suppresses the metastasis of CD73+ tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

CD73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4589050

10.1080/2162402X.2015.1046675

2 October 2017

Identifiers

DOI

1 reference

12 August 2017

1 reference

PMC publication ID

4589050

12 August 2017

PubMed publication ID

26451321

1 reference

PMC publication ID

4589050